<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72D3BE82-7A22-490E-AFCF-06D8EEF58D0B"><gtr:id>72D3BE82-7A22-490E-AFCF-06D8EEF58D0B</gtr:id><gtr:name>Angers University Hospital (CHU Angers)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Neuroscience</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6"><gtr:id>0FA0D9A7-79AE-46F8-85E8-D5DB38EE49E6</gtr:id><gtr:name>Hebrew University of Jerusalem</gtr:name><gtr:address><gtr:line1>Mt Scopus</gtr:line1><gtr:line4>Jerusalem</gtr:line4><gtr:line5>91905</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72D3BE82-7A22-490E-AFCF-06D8EEF58D0B"><gtr:id>72D3BE82-7A22-490E-AFCF-06D8EEF58D0B</gtr:id><gtr:name>Angers University Hospital (CHU Angers)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CEB540EB-ABDC-478D-9603-4B8FDCE01F15"><gtr:id>CEB540EB-ABDC-478D-9603-4B8FDCE01F15</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:surname>Yu Wai Man</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002570"><gtr:id>E7953F7B-88F9-43CC-9B44-B33596BD4112</gtr:id><gtr:title>What disease mechanisms contribute to multisystem tissue involvement in dominant optic atrophy due to OPA1 mutations?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002570</gtr:grantReference><gtr:abstractText>Autosomal dominant optic atrophy (DOA) affects the optic nerve, causing insidious visual loss from early childhood. It is the most common inherited optic nerve disorder and the majority of patients carry mutations in OPA1, a nuclear gene critical for normal mitochondrial function. Mitochondria are essential components of all human cells, containing multiple copies of their own DNA (MtDNA), and forming long branching networks which fuel the cell?s energy requirements.

About 20% of patients with OPA1 mutations will develop a more severe form of the disease (DOA+), associated with a worse visual prognosis and additional neurological complications. The risk of developing DOA+ is three times higher with missense mutations located within the GTPase gene region. Using a range of human tissue samples, I will investigate whether this specific mutational subgroup results in greater fragmentation of the mitochondrial network and more marked mtDNA damage, thus contributing to accelerated cell death. I will also explore the possibility of rescuing the fragmentation defect by manipulating the level of expression of OPA1 and other mitochondrial proteins involved in network fusion and fission. Visual loss in DOA is progressive and the neurological features develop in later life, providing a clear window of opportunity for therapeutic intervention.</gtr:abstractText><gtr:technicalSummary>Autosomal dominant optic atrophy (DOA) is the most common inherited optic nerve disorder and the majority of patients harbour pathogenic OPA1 mutations. Although DOA is characterised by the preferential loss of retinal ganglion cells (RGC), about 20% of OPA1 carriers will develop a more severe form of the disease (DOA+), associated with a worse visual prognosis and additional debilitating neurological complications. The risk of developing DOA+ is three times higher with missense OPA1 mutations affecting the catatytic GTPase domain. I will explore the pathogenenetic mechanisms underlying this key observation by comparing tissue samples; skeletal muscle biopsies, fibroblasts, and myoblasts, collected from DOA+ patients with missense GTPase mutations (n=10), and pure DOA patients carrying frameshift deletions (n=5) and splice site mutations (n=5).

(i) Do missense OPA1 GTPase mutations result in increased mitochondrial network fragmentation?
OPA1 is a mitochondrial inner membrane protein with important pro-fusional properties. In conjunction with the mitochondrial outer membrane proteins MFN1 and MFN2, OPA1 counterbalances the influence of hFIS1 and DRP1, two pro-fission proteins found in the mitochondrial outer membrane and cytosol, respectively. Our preliminary data suggest that missense GTPase mutations lead to greater mitochondrial fragmentation compared with other OPA1 mutational subgroups. I will confirm these initial findings, investigating at the same time the pathological consequences of the observed fragmentation defect on cellular function and viability.

(ii) Do missense OPA1 GTPase mutations lead to greater mitochondrial DNA (mtDNA) instability? 
Our pilot data, based on next-generation ultra-deep-sequencing, suggest that OPA1 GTPase mutations result in greater mtDNA instability. I will therefore compare the pattern and mutational burden of somatic mtDNA abnormalities in a larger group of DOA+ and pure DOA patients, relating them to two classical disorders of mtDNA maintenance (POLG1 and PEO1), and to normal ageing. I will use the generated biological data to model possible OPA1 disease mechanisms leading to accelerated mtDNA mutagenesis and the development of DOA+ features.

(iii) Are these deleterious consequences secondary to a dominant-negative effect?
HEK293 cells will be transfected with mutant cDNA extracted from OPA1 fibroblasts harbouring missense GTPase mutations. If these mutations exert a dominant-negative effect, mitochondrial fragmentation will be observed despite normal levels of the endogenous, wild-type OPA1 protein. Finally, I will explore the possibility of rescuing the fragmentation phenotype by manipulating the expression of the major pro-fusion and pro-fission mitochondrial proteins. These experiments could pave the way for gene therapy aimed initially at halting RGC loss and progressive visual decline.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>898143</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Angers University Hospital (CHU Angers)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Biochemistry and Genetics</gtr:department><gtr:description>Angers OPA1 Collaboration</gtr:description><gtr:id>9DCFBCE2-24D9-4607-9676-71F151D80269</gtr:id><gtr:impact>PMID:20974897
PMID:20157015</gtr:impact><gtr:outcomeId>nLbecGjd1Qj-1</gtr:outcomeId><gtr:partnerContribution>Exchange of patient data and tissue samples</gtr:partnerContribution><gtr:piContribution>Exchange of patient data and tissue samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eberhard Karls University of Tubingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute for Ophthalmic Research</gtr:department><gtr:description>Tuebingen OPA1 Mouse Collaboration</gtr:description><gtr:id>EB1F7BBB-48BE-43D0-81EA-E783EF321096</gtr:id><gtr:impact>PMID: 19815013
PMID: 19181907</gtr:impact><gtr:outcomeId>4C924CBA2F4-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators in Tuebingen have provided us with tissues from a second OPA1 mouse model of dominant optic atrophy - different from the Cardiff one.</gtr:partnerContribution><gtr:piContribution>I have analysed these OPA1 mouse tissues as part of my ongoing PhD research project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Optometry and Vision Sciences</gtr:department><gtr:description>Cardiff OPA1 Mouse Collaboration</gtr:description><gtr:id>32BDC108-2988-49EF-92B1-84A5F7FF5C6B</gtr:id><gtr:impact>PMID: 19443720
PMID: 20157015</gtr:impact><gtr:outcomeId>0DB41A7F3A1-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators in Cardiff have provided us with tissues from an OPA1 mouse model of dominant optic atrophy.</gtr:partnerContribution><gtr:piContribution>I have analysed these OPA1 mouse tissues as part of my ongoing PhD research project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bologna</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Neurologial Sciences</gtr:department><gtr:description>Bologna OPA1 Collaboration</gtr:description><gtr:id>F1FC0540-99F9-455D-AF4F-169E6A631525</gtr:id><gtr:impact>PMID: 20974897
PMID: 20157015</gtr:impact><gtr:outcomeId>PhZ8E8vPjct-1</gtr:outcomeId><gtr:partnerContribution>Dr Carelli's team have provided us with clinical data for a meta-analysis of the phenotypes seen in patients with OPA1 mutations.</gtr:partnerContribution><gtr:piContribution>We are working closely with Dr Carelli's team in Bologa to understand the development of multisystem disease in patients harbouring OPA1 mutations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moorfields Eye Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Moorfields Biomedical Research Centre</gtr:department><gtr:description>Moorfields BRC Collaboration</gtr:description><gtr:id>5616A9CB-9DF9-490C-B29B-574646F2863E</gtr:id><gtr:impact>Joint application to the NIHR Rare Diseases Translational Research Collaboration.</gtr:impact><gtr:outcomeId>pm7Serhjk6V-1</gtr:outcomeId><gtr:partnerContribution>Access to advanced psychophysical testing for the deep phenotyping of patients with inherited optic neuropathies.</gtr:partnerContribution><gtr:piContribution>Patients with inherited optic neuropathies and a confirmed molecular diagnosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Institute of Neuroscience Montpellier</gtr:department><gtr:description>Montpellier OPA1 Collaboration</gtr:description><gtr:id>7B4EAFCB-9D84-46A6-AF5B-31C322CC8B6A</gtr:id><gtr:impact>PMID: 20974897
PMID: 20157015</gtr:impact><gtr:outcomeId>YPHdarMLtNn-1</gtr:outcomeId><gtr:partnerContribution>Dr Leaners' team have provided tissue samples and experimental data for our research in Newcastle.</gtr:partnerContribution><gtr:piContribution>We are working with Dr Guy Lenaers team in Montpellier to investigate the role of OPA1 in mitochondrial DNA replication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hebrew University of Jerusalem</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Hebrew University Hadassah Medical School</gtr:department><gtr:description>Jerusalem Hadassah Collaboration</gtr:description><gtr:id>AE48345D-DC65-4459-8FD3-03650DF61B8C</gtr:id><gtr:impact>PMID: 26561570</gtr:impact><gtr:outcomeId>56c1155c6b2193.39210621-1</gtr:outcomeId><gtr:partnerContribution>Provision of tissue samples from patients with inherited neurodegenerative diseases.</gtr:partnerContribution><gtr:piContribution>Analysis of tissue samples from patients with inherited neurodegenerative diseases.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>UK LHON Patient Network</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F7BDFD4-052A-4010-9286-E5E907CB81BC</gtr:id><gtr:impact>LHON (Leber hereditary optic neuropathy) is an important cause of irreversible blindness among young adults and treatment options are currently limited. Over the past two years, I have been working closely with families that have been affected by LHON in the UK through regular small group meetings and e-mail discussions.

The engagement activities described earlier have lead to the setting up a UK LHON charity to support patients and their families (http://www.lhonsociety.org/).</gtr:impact><gtr:outcomeId>54497b1fd5ce23.93363596</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.lhonsociety.org/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENMC workshop on neuromuscular disorders of mitochondrial fusion and fission</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FC367830-E1B4-4FD5-9618-162CACC95C2A</gtr:id><gtr:impact>Organisers:
Dr. Patrick Yu-Wai-Man (Newcastle, UK); Dr. Valerio Carelli (Bologna, Italia); Prof. Patrick F. Chinnery (Newcastle, UK) 

Description:
The 197th ENMC workshop entitled &amp;quot;Neuromuscular disorders of mitochondrial fusion and fission - molecular mechanisms and therapeutic strategies&amp;quot; took place from the 26th to the 28thof April 2013 in Naarden, The Netherlands. A multidisciplinary group of 19 participants took part in this workshop, including 18 clinical and basic science researchers from 6 different countries (France, Germany, Italy, Spain, the UK, and the USA), and 1 patient representative from CMT UK.

The first half of this workshop reviewed the fundamental and interrelated roles mediated by the MFN2 and OPA1 proteins in normal cellular function. The pathogenetic mechanisms directly implicated in the development of CMT2A and DOA were discussed in the context of both in vitro and in vivo disease models. In the second half of this workshop, the participants collectively described the range of clinical features linked to MFN2 and OPA1 mutations, including novel disease manifestations and the natural history of this heterogeneous group of disorders. The final session focused on how to translate recent scientific advances for the benefit of patients and the best way to design future clinical trials in this challenging area of research. 

The following key deliverables were achieved:

1.A comprehensive description of the expanding neuromuscular phenotypes associated with pathogenic MFN2 and OPA1 mutations.

2.Collaborative biobank access to patient tissue samples and animal models to further explore fundamental disease mechanisms in CMT-2A and DOA.

3.Pooled clinical registry of well-characterised patient cohorts for the purpose of future clinical studies, including treatment trials.</gtr:impact><gtr:outcomeId>54497bb230fec6.84773293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.enmc.org/workshops/workshop-reports/neuromuscular-disorders-mitochondrial-fusion-and-fission-molecular-mechanisms-and-therapeutic-strategies</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Rare Diseases Translational Research Collaboration</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A93EC831-7EE9-473F-B25D-89A2B60910EE</gtr:id><gtr:outcomeId>jJnNkVPVorF</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Early Career Award</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4829C5CA-1101-4CA3-BFEA-9F2733D04D2A</gtr:id><gtr:outcomeId>cSG3rrrLvEN</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Moorfields Special Trustees Research Award</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Moorfields Eye Charity</gtr:fundingOrg><gtr:id>4558C7BA-857F-412D-9ABD-C9D6931CBF3B</gtr:id><gtr:outcomeId>58ae25eef2da38.28095934</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>310000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Rare Diseases Translational Research Collaboration</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>BA22E353-7213-4E91-A061-27F5A32C369D</gtr:id><gtr:outcomeId>56c11637344bf0.94684378</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>805331FF-C863-43D2-AE9F-73FF3832B4B4</gtr:id><gtr:title>Both mitochondrial DNA and mitonuclear gene mutations cause hearing loss through cochlear dysfunction.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d406079946f3d96dfc81e3954f097e6"><gtr:id>5d406079946f3d96dfc81e3954f097e6</gtr:id><gtr:otherNames>Kullar PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58a4eb8654d079.10899858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C73A867-1930-4CF0-9EA3-449BA899A6B2</gtr:id><gtr:title>Traumatic optic neuropathy-Clinical features and management issues.</gtr:title><gtr:parentPublicationTitle>Taiwan journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2211-5056</gtr:issn><gtr:outcomeId>5675e60b1f7f4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5810B1DF-A8D9-4D92-BA49-CA83CFF20E65</gtr:id><gtr:title>Raised intraocular pressure as a potential risk factor for visual loss in Leber Hereditary Optic Neuropathy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f66f58488679f6122ce10c4e43a78fd9"><gtr:id>f66f58488679f6122ce10c4e43a78fd9</gtr:id><gtr:otherNames>Thouin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13449_29_23667621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32D450E4-8505-444F-98A2-CC52A3931561</gtr:id><gtr:title>Loss of function ofin mice induces deafness and cochlear outer hair cells' degeneration.</gtr:title><gtr:parentPublicationTitle>Cell death discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21ab813cf3529feeacd5df737851b9a3"><gtr:id>21ab813cf3529feeacd5df737851b9a3</gtr:id><gtr:otherNames>Buret L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2058-7716</gtr:issn><gtr:outcomeId>58a4eb871409f7.47762865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B49C80-A31F-4506-B93F-F7B8D14A1BE2</gtr:id><gtr:title>The m.13051G&amp;gt;A mitochondrial DNA mutation results in variable neurology and activated mitophagy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d5497e8825172e97b79fc5ceffcbfd2"><gtr:id>6d5497e8825172e97b79fc5ceffcbfd2</gtr:id><gtr:otherNames>Dombi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58a4eb86c8ab07.81445736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>053D4173-0EC9-4B8C-933F-CDBA95E74DA8</gtr:id><gtr:title>Reply: Are CHCHD10 mutations indeed associated with familial amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5675dc6f8d1c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EAE6C56-DDEC-4575-BA4B-0A4489B3D4B5</gtr:id><gtr:title>Harnessing the Power of Genetic Engineering for Patients With Mitochondrial Eye Diseases.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1070-8022</gtr:issn><gtr:outcomeId>58a4eb83d53374.68212825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46E09D05-2C3D-4BA1-A10A-24DEE6ECD07E</gtr:id><gtr:title>Reply: A distinct clinical phenotype in a German kindred with motor neuron disease carrying a CHCHD10 mutation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56bfcec0bdbf44.49073563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14850285-CCB0-449E-AA51-37609311CF79</gtr:id><gtr:title>Inherited eye-related disorders due to mitochondrial dysfunction.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a9c20beddec99.46620753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>760A2A45-84A3-4E3A-972D-B7446D2F6DF5</gtr:id><gtr:title>Clinical utility gene card for: Wolfram syndrome.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca156e6df4ad3e8526f06caa371e7fbf"><gtr:id>ca156e6df4ad3e8526f06caa371e7fbf</gtr:id><gtr:otherNames>Moosajee M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>58a4eb85267534.96487567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>616F1CB9-D556-4808-971B-1C5D7F835573</gtr:id><gtr:title>Visual and psychological morbidity among patients with autosomal dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9722f6428465edb963f5cd639e62f91"><gtr:id>a9722f6428465edb963f5cd639e62f91</gtr:id><gtr:otherNames>Bailie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>pm_13449_29_23452392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03EE9768-CC9C-4FED-A2BA-F6C550901269</gtr:id><gtr:title>Extraocular muscle atrophy and central nervous system involvement in chronic progressive external ophthalmoplegia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97b274883a1e43c32b7d3477aca9ca99"><gtr:id>97b274883a1e43c32b7d3477aca9ca99</gtr:id><gtr:otherNames>Yu-Wai-Man C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544972b5760793.65427925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>731E3A1B-5F03-4786-8432-7D5446249D6E</gtr:id><gtr:title>Exome sequencing in undiagnosed inherited and sporadic ataxias.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56bfcec1b00e74.42090222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7313734-DD72-4569-9E98-CB616A6FD63C</gtr:id><gtr:title>The Pattern of Retinal Ganglion Cell Loss in OPA1-Related Autosomal Dominant Optic Atrophy Inferred From Temporal, Spatial, and Chromatic Sensitivity Losses.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b59fc60f985bd8aacf9bde6a7f490cf9"><gtr:id>b59fc60f985bd8aacf9bde6a7f490cf9</gtr:id><gtr:otherNames>Majander A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>58a4eb845b95a0.80474872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF858E00-1E72-4F95-8772-FF5689C430D7</gtr:id><gtr:title>A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95e0e2e3a26092c6978e249e8affaa09"><gtr:id>95e0e2e3a26092c6978e249e8affaa09</gtr:id><gtr:otherNames>Rouzier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a6d858c24f196.38993141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55DCD6F6-4E80-40AE-AE7C-616B5CDDE739</gtr:id><gtr:title>A multiple sclerosis-like disorder in patients with OPA1 mutations.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>58a4eb855f22c2.16287739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28E656A6-152E-4F89-993F-054D0538B359</gtr:id><gtr:title>Homozygous deletion in MICU1 presenting with fatigue and lethargy in childhood.</gtr:title><gtr:parentPublicationTitle>Neurology. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca96d1966f0778644c32e881ef5a5f3d"><gtr:id>ca96d1966f0778644c32e881ef5a5f3d</gtr:id><gtr:otherNames>Lewis-Smith D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2376-7839</gtr:issn><gtr:outcomeId>58a4eb868bd9a4.47360552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF54BA07-2F29-4598-9A5B-75874E4B923C</gtr:id><gtr:title>Genetic manipulation for inherited neurodegenerative diseases: myth or reality?</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>58a4eb85d120b3.08054056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>597BF41B-AD57-4F13-99A8-20B9B85401AE</gtr:id><gtr:title>Recessive Mutations in RTN4IP1 Cause Isolated and Syndromic Optic Neuropathies.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5372d563a7bb47af0e0d4f7f0e0af9da"><gtr:id>5372d563a7bb47af0e0d4f7f0e0af9da</gtr:id><gtr:otherNames>Angebault C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56bfcebfcfac40.27199436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB8EFF1D-00D6-4830-B963-7F6D8F78ECB0</gtr:id><gtr:title>Mitochondrial donation--how many women could benefit?</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56bfcec17fd426.40565102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1BE1345-35DA-47FF-AC66-4E1397399C5C</gtr:id><gtr:title>Diagnostic investigations of patients with chronic progressive external ophthalmoplegia.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>pm_13449_29_23024221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58D7201B-85D7-43FF-AD2B-B637DAB597B7</gtr:id><gtr:title>New treatments for mitochondrial disease-no time to drop our standards.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_13449_29_23817350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E816188-C47D-4D54-B8E4-CA52D6E88DE7</gtr:id><gtr:title>Surgery for traumatic optic neuropathy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5a9c20bf4096d9.84676257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E99BEA0-0806-47B1-BDE6-7A889B2DAD6E</gtr:id><gtr:title>Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56bfcec1266641.28155999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0020CD67-8C81-4F24-9D90-BACFA8835B5C</gtr:id><gtr:title>Erratum to: The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89b31b53bd8d22167e3e61b6f878f7e4"><gtr:id>89b31b53bd8d22167e3e61b6f878f7e4</gtr:id><gtr:otherNames>Guthrie G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56bfcebecf35f2.97578516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB439C96-8920-4C54-91F0-4D64577CB802</gtr:id><gtr:title>Mitochondrial dysfunction in glaucoma: closing the loop.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>pm_13449_29_22547661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65CB86C4-34F6-47E0-A16E-13DF806070A9</gtr:id><gtr:title>A neurodegenerative perspective on mitochondrial optic neuropathies.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>58a4eb84df0062.74597997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3CABAD7-9712-4916-97BC-F226AB35E991</gtr:id><gtr:title>Disturbed mitochondrial dynamics and neurodegenerative disorders.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2bc8ccf2f361fa8c5a2eebff8fa9de"><gtr:id>1f2bc8ccf2f361fa8c5a2eebff8fa9de</gtr:id><gtr:otherNames>Burt? F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>56bfcd19dc2223.53537248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81CF62C5-61B9-4EAE-8141-D2191E9CFD6B</gtr:id><gtr:title>The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58a4eb861ae7c5.26791576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>375B6522-CEE4-437F-BB22-D8EE104D3709</gtr:id><gtr:title>A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b3991009.65156799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30EDC10F-E33D-48B5-8A09-E4CE3C8A0530</gtr:id><gtr:title>Prevalence of neurogenetic disorders in the North of England.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c967a786847e7e5db1d802a30f49fbb9"><gtr:id>c967a786847e7e5db1d802a30f49fbb9</gtr:id><gtr:otherNames>Bargiela D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56bfcec02c3807.25811329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F8E2194-3E89-4890-9667-ED773E505CA1</gtr:id><gtr:title>Near-identical segregation of mtDNA heteroplasmy in blood, muscle, urinary epithelium, and hair follicles in twins with optic atrophy, ptosis, and intractable epilepsy.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9324030e73eb3a5421a31ea80edbd26"><gtr:id>d9324030e73eb3a5421a31ea80edbd26</gtr:id><gtr:otherNames>Spyropoulos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>544972b5499058.78081155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D67F35A-06D3-46A4-8055-3891DEC73ABD</gtr:id><gtr:title>Disorders of the optic nerve in mitochondrial cytopathies: new ideas on pathogenesis and therapeutic targets.</gtr:title><gtr:parentPublicationTitle>Current neurology and neuroscience reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110e3dc589769ce84dec29b85162fcd3"><gtr:id>110e3dc589769ce84dec29b85162fcd3</gtr:id><gtr:otherNames>Sitarz KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1528-4042</gtr:issn><gtr:outcomeId>pm_13449_29_22392506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA977A2-C470-427A-B66E-88B8EB39C4BC</gtr:id><gtr:title>OPA1 mutations induce mtDNA proliferation in leukocytes of patients with dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110e3dc589769ce84dec29b85162fcd3"><gtr:id>110e3dc589769ce84dec29b85162fcd3</gtr:id><gtr:otherNames>Sitarz KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_13449_29_22993284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56184130-38E7-434F-AB9B-2AD50086ACF9</gtr:id><gtr:title>Lamination of the Outer Plexiform Layer in Optic Atrophy Caused by Dominant WFS1 Mutations.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b59fc60f985bd8aacf9bde6a7f490cf9"><gtr:id>b59fc60f985bd8aacf9bde6a7f490cf9</gtr:id><gtr:otherNames>Majander A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn><gtr:outcomeId>58a4eb859145c6.28222260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>393EB5E3-6BDF-4499-AAAD-26C796F4C7A5</gtr:id><gtr:title>Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies.</gtr:title><gtr:parentPublicationTitle>Journal of neuromuscular diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bdc173cc903af2b23be1f55ff257851"><gtr:id>1bdc173cc903af2b23be1f55ff257851</gtr:id><gtr:otherNames>Bartsakoulia M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a4ebc90c4d96.91277767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>292ADD08-3281-42E8-AF35-863542040C35</gtr:id><gtr:title>CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c3b332cbef779a7f83a52cbb472984b"><gtr:id>8c3b332cbef779a7f83a52cbb472984b</gtr:id><gtr:otherNames>Genin EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>56bfcebf7ebf31.99906661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49A132FC-D10E-4409-B603-192DC6F0F2DF</gtr:id><gtr:title>Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn><gtr:outcomeId>pm_13449_29_23916084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>522DA450-AFA2-4CA6-9C7C-DA47DEE0BA0A</gtr:id><gtr:title>Prominent sensorimotor neuropathy due to SACS mutations revealed by whole-exome sequencing.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>pm_13449_29_22751902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63707AA6-3148-4B94-8755-38506572ADC4</gtr:id><gtr:title>Steroids for traumatic optic neuropathy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>544972b5aa62c0.82712509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE4C7DB8-A7A1-48D3-AD12-68D5770F0633</gtr:id><gtr:title>Reply: 'Behr syndrome' with OPA1 compound heterozygote mutations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b3083244.19023982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C461DD0-2C61-475A-8567-75F7BA98D78E</gtr:id><gtr:title>Dysfunctional mitochondrial maintenance: what breaks the circle of life?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13449_29_22271662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>788DA055-413D-4315-ADDD-32AC2D77F482</gtr:id><gtr:title>MFN2 mutations cause compensatory mitochondrial DNA proliferation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110e3dc589769ce84dec29b85162fcd3"><gtr:id>110e3dc589769ce84dec29b85162fcd3</gtr:id><gtr:otherNames>Sitarz KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13449_29_22492563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AC0EF62-B9AF-4E9B-9A3D-AF773510981A</gtr:id><gtr:title>Neuro-Ophthalmology in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1070-8022</gtr:issn><gtr:outcomeId>56bfcec0ecc1d4.78117822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D0A2FA7-870D-4D95-9F13-9F9C6E8DDE74</gtr:id><gtr:title>Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e2b35510da18c4d24ede0199ba63a6c"><gtr:id>4e2b35510da18c4d24ede0199ba63a6c</gtr:id><gtr:otherNames>Liao C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58a4eb8499ba94.17918863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BB42EDD-8AD4-46C6-9094-484D84E0EB2F</gtr:id><gtr:title>Leber's hereditary optic neuropathy with late disease onset: clinical and molecular characteristics of 20 patients.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c6987dacabce24bde09808b699b63"><gtr:id>334c6987dacabce24bde09808b699b63</gtr:id><gtr:otherNames>Dimitriadis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>56bfcda8e1f5e3.03391736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD85C933-B3DC-4BAB-9E93-0BD4CE20E34A</gtr:id><gtr:title>Reply: Is CHCHD10 Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56bfcec0840af0.86761516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C34058-EC49-49B0-910A-8BD6C8B75102</gtr:id><gtr:title>Reply: Parsing the differences in affected with LHON: genetic versus environmental triggers of disease conversion.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56bfcebf084a63.01865212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>898D2D14-3477-4FCB-BB75-9067538E9B15</gtr:id><gtr:title>Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebed1cd795e0af5789caf713577a49fc"><gtr:id>ebed1cd795e0af5789caf713577a49fc</gtr:id><gtr:otherNames>Giordano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b4a59cb7.34696577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7839D7D8-6E53-4EFE-AB23-737CAA9AB504</gtr:id><gtr:title>Genetic variations within the OPA1 gene are not associated with neuromyelitis optica.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110e3dc589769ce84dec29b85162fcd3"><gtr:id>110e3dc589769ce84dec29b85162fcd3</gtr:id><gtr:otherNames>Sitarz KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>C49b8szagLE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2532F31D-45EF-4EC1-AF8E-2A8A79B706A3</gtr:id><gtr:title>Late-onset sacsinopathy diagnosed by exome sequencing and comparative genomic hybridization.</gtr:title><gtr:parentPublicationTitle>Journal of neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-7063</gtr:issn><gtr:outcomeId>544972b514a280.81859459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB2D8421-9C97-4439-A239-1FD4D55773E2</gtr:id><gtr:title>Reply: Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b3397d02.26081146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F928227-6BA4-4D1A-8029-ABD2A8F4C914</gtr:id><gtr:title>The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89b31b53bd8d22167e3e61b6f878f7e4"><gtr:id>89b31b53bd8d22167e3e61b6f878f7e4</gtr:id><gtr:otherNames>Guthrie G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_13449_29_23238845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCB7A5F0-6406-42ED-9A54-872C951B2378</gtr:id><gtr:title>Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>58a4eb84200ff4.71530285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D51A6E6C-AC6F-4AEC-A354-410851F3B588</gtr:id><gtr:title>Reply: Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b2c8c5b6.27722924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB1ABE2F-CCD0-4107-B0FB-EBF3581C49C3</gtr:id><gtr:title>Universal heteroplasmy of human mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13449_29_23077218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7374D98B-D6EA-4D02-BAC8-ADAFEB6A9F42</gtr:id><gtr:title>197th ENMC international workshop: Neuromuscular disorders of mitochondrial fusion and fission - OPA1 and MFN2 molecular mechanisms and therapeutic strategies: 26-28 April 2013, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>544972b3d877a7.65750366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50433280-03D8-44D2-A085-D8A6243C0E55</gtr:id><gtr:title>Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6eb36c645750836ba7b7fb501797c8d9"><gtr:id>6eb36c645750836ba7b7fb501797c8d9</gtr:id><gtr:otherNames>Klopstock T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13449_29_23388409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C464AF37-28CA-48AA-8C70-5416922E46CC</gtr:id><gtr:title>Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b40efcb5.81929842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>014C1556-12FA-4078-B122-BC90D763B544</gtr:id><gtr:title>Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>544972b46e0d47.86504164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EF3F077-45DD-4763-9705-5C1BCD951A15</gtr:id><gtr:title>Reply: Early-onset Behr syndrome due to compound heterozygous mutations in OPA1.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544972b36561f1.56440234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FEB075B-7B1E-4E86-A4CD-C4298E831268</gtr:id><gtr:title>Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>544972b4d569f7.72455775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F169C56-375F-4E8E-A019-DC512D6655A5</gtr:id><gtr:title>Treatment strategies for inherited optic neuropathies: past, present and future.</gtr:title><gtr:parentPublicationTitle>Eye (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-222X</gtr:issn><gtr:outcomeId>544972b43e6278.91465272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38831EC0-CA72-4FA2-860B-DDBB42563162</gtr:id><gtr:title>Reply: Sensorineural hearing loss in OPA1-linked disorders.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13449_29_23650221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D2BE1BC-6FE3-4C75-A433-EE0E10649D19</gtr:id><gtr:title>Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900f2596778f7b8a20c902800109b43b"><gtr:id>900f2596778f7b8a20c902800109b43b</gtr:id><gtr:otherNames>Spiegel R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>56bfcebe9504b4.19672682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD436263-ABFD-4CD7-98B2-859EBCD0E545</gtr:id><gtr:title>Therapeutic Approaches to Inherited Optic Neuropathies.</gtr:title><gtr:parentPublicationTitle>Seminars in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0271-8235</gtr:issn><gtr:outcomeId>56bfcec05cefd2.39982001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B298323-329C-4FD8-B90F-57F81ACA7DF3</gtr:id><gtr:title>Behr's Syndrome is Typically Associated with Disturbed Mitochondrial Translation and Mutations in theGene.</gtr:title><gtr:parentPublicationTitle>Journal of neuromuscular diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-4581</gtr:issn><gtr:outcomeId>5675ebab9a419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>603D283B-402D-4970-89A4-C48E2A36D6EB</gtr:id><gtr:title>Delayed Optochiasmal Arachnoiditis following Intervention for a Subarachnoid Haemorrhage.</gtr:title><gtr:parentPublicationTitle>Ophthalmology international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1431</gtr:issn><gtr:outcomeId>5675e0409025f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F6608C7-BF31-409B-892C-722C10A1042C</gtr:id><gtr:title>Reply: CHCHD10 mutations in Italian patients with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5675de75dee8b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A73BB7FE-CF70-42FD-9F36-4DB343046640</gtr:id><gtr:title>Reply: High prevalence of CHCHD10 mutations in patients with frontotemporal dementia from China.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7001a629b2674273a8490bc6a5efa6a3"><gtr:id>7001a629b2674273a8490bc6a5efa6a3</gtr:id><gtr:otherNames>Bannwarth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56bfcebf342909.81372747</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002570</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>